Minimally invasive surgery associated with worse survival for women with cervical cancer compared to open hysterectomy
When comparing standard-of-care surgical options for women with early-stage cervical cancer, two studies led by researchers at The University of Texas MD Anderson Cancer Center discovered that minimally invasive radical hysterectomy is associated with higher recurrence rates and worse overall survival (OS), compared to abdominal radical hysterectomy.
The results of both studies are published today in the New England Journal of...
MD Anderson slates third annual Boot Walk to End Cancer®
Thanks to a grassroots campaign at Houston-area Walmart stores and generous support from individuals, teams and other corporate sponsors,...
Suppression of DKK3 protein thwarts pancreatic tumor progression and prolongs survival
Researchers at The University of Texas MD Anderson Cancer Center have shed new light on why pancreatic tumors are so resistant to therapy....
Frances MacDonald receives Brown Foundation Award for Excellence in Oncology Nursing
Frances MacDonald, a clinical nurse in the GI-Colorectal Center at The University of Texas MD Anderson Cancer Center, is the recipient of the 2018 Brown Foundation Award for Excellence in Oncology Nursing.
The award, established by The Brown Foundation Inc. in 1982, is the institution's highest nursing honor. A committee of MD Anderson clinical faculty, patient care administrators and nursing staff, led by Carol Porter, senior...
RNA thought to spread cancer shows ability to suppress breast cancer metastasis
Researchers at The University of Texas MD Anderson Cancer Center have discovered that a form of RNA called metastasis-associated lung adenocarcinoma...
Study shows surgery, radiation extend survival of patients with limited metastatic lung cancer
Radiation or surgical removal of metastatic tumors provides a major survival advantage for lung cancer patients with minimal stage 4 disease...
Cancer patients with rare deadly brain infection treated successfully with off-the-shelf adoptive T-cell therapy in clinical trial
An emerging treatment known as adoptive T-cell therapy has proven effective in a Phase II clinical trial for treating progressive multifocal...
MD Anderson and Cyclacel Pharmaceuticals announce strategic alliance to study novel Cyclacel medicines in hematological malignancies
The University of Texas MD Anderson Cancer Center and Cyclacel Pharmaceuticals, Inc., today announced a three-year strategic alliance agreement...
MD Anderson immunologist Jim Allison awarded Nobel Prize
Jim Allison, Ph.D., chair of Immunology and executive director of the immunotherapy platform at The University of Texas MD Anderson Cancer...